Clinical Trial Results:
A 12-week Phase IIa, Double-blind, Placebo-controlled, Randomised Study to Investigate the Efficacy and Safety of AZD7624 in COPD Patients with a History of Frequent Acute Exacerbations while on Maintenance Therapy
Summary
|
|
EudraCT number |
2014-001053-16 |
Trial protocol |
NL |
Global end of trial date |
04 Apr 2016
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
19 Apr 2017
|
First version publication date |
19 Apr 2017
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
D2550C00005
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
AstraZeneca AB
|
||
Sponsor organisation address |
Södertälje, Stockholm, Sweden, 151 85
|
||
Public contact |
Ziad Taib, AstraZeneca AB, 46 708 46 73 56, ziad.taib@astrazeneca.com
|
||
Scientific contact |
Ziad Taib, AstraZeneca AB, 46 708 46 73 56, ziad.taib@astrazeneca.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
03 Oct 2016
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
04 Apr 2016
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
04 Apr 2016
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To compare the effects of AZD7624 versus placebo on the time to first event of moderate or severe COPD exacerbations or early drop-out related to worsening of COPD symptoms (i.e., composite endpoint referred to as “ExDo”) in patients with COPD on maintenance treatment with at least ICS and LABA.
|
||
Protection of trial subjects |
This study was performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with the International Council for Harmonisation (ICH)/Good Clinical Practice (GCP) and applicable regulatory requirements and the AstraZeneca policy on Bioethics and Human Biological Samples.
Each subject was given full and adequate oral and written information about the nature, purpose, possible risk and benefit of the study and it was ensured that the Informed Consent Form (ICF) was signed and dated before any study specific procedure was performed.
Opportunity was given to ask questions and subjects were allowed time to consider the information provided. Subjects were also notified that they were free to discontinue from the study at any time. A copy of the signed ICF was provided to the subjects.
Written informed consent was obtained from all healthy subjects prior to initiation of the study.
|
||
Background therapy |
Stable COPD maintenance treatment with at least inhaled corticosteroids (ICS) and long-acting beta agonist (LABA) for at least 2 months prior to enrolment (Visit 1), to be continued unchanged during the study. | ||
Evidence for comparator |
A placebo comparator was used in this study. | ||
Actual start date of recruitment |
28 Oct 2014
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Argentina: 80
|
||
Country: Number of subjects enrolled |
United States: 74
|
||
Country: Number of subjects enrolled |
Chile: 14
|
||
Country: Number of subjects enrolled |
Netherlands: 13
|
||
Country: Number of subjects enrolled |
Peru: 19
|
||
Country: Number of subjects enrolled |
South Africa: 13
|
||
Worldwide total number of subjects |
213
|
||
EEA total number of subjects |
13
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
104
|
||
From 65 to 84 years |
109
|
||
85 years and over |
0
|
|
||||||||||||||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||||||||||||||
Recruitment details |
- | |||||||||||||||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||||||||||||||
Screening details |
Of the total 327 patients enrolled into the study, 114 were not randomised. The majority of these were due to screening failures. | |||||||||||||||||||||||||||||||||
Pre-assignment period milestones
|
||||||||||||||||||||||||||||||||||
Number of subjects started |
327 [1] | |||||||||||||||||||||||||||||||||
Number of subjects completed |
213 | |||||||||||||||||||||||||||||||||
Pre-assignment subject non-completion reasons
|
||||||||||||||||||||||||||||||||||
Reason: Number of subjects |
Adverse event, non-fatal: 6 | |||||||||||||||||||||||||||||||||
Reason: Number of subjects |
not specified: 1 | |||||||||||||||||||||||||||||||||
Reason: Number of subjects |
Consent withdrawn by subject: 10 | |||||||||||||||||||||||||||||||||
Reason: Number of subjects |
Protocol deviation: 97 | |||||||||||||||||||||||||||||||||
Notes [1] - The number of subjects reported to have started the pre-assignment period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same. Justification: The country of the subject was only databased and tabulated for subjects randomized into the study. The country for screening failures is not included in the table of Subject number per country. |
||||||||||||||||||||||||||||||||||
Period 1
|
||||||||||||||||||||||||||||||||||
Period 1 title |
Treatment Period (overall period)
|
|||||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||||||||||||||
Blinding used |
Double blind | |||||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator, Monitor | |||||||||||||||||||||||||||||||||
Arms
|
||||||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||||||||||||||
Arm title
|
AZD7624 1.0 mg | |||||||||||||||||||||||||||||||||
Arm description |
- | |||||||||||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||||||||||
Investigational medicinal product name |
AZD7624
|
|||||||||||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Inhalation solution, Inhalation solution
|
|||||||||||||||||||||||||||||||||
Routes of administration |
Inhalation use, Inhalation use
|
|||||||||||||||||||||||||||||||||
Dosage and administration details |
2 x 0.5 mg inhalation once daily
|
|||||||||||||||||||||||||||||||||
Arm title
|
Placebo | |||||||||||||||||||||||||||||||||
Arm description |
- | |||||||||||||||||||||||||||||||||
Arm type |
Placebo | |||||||||||||||||||||||||||||||||
Investigational medicinal product name |
placebo
|
|||||||||||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Inhalation solution
|
|||||||||||||||||||||||||||||||||
Routes of administration |
Inhalation use
|
|||||||||||||||||||||||||||||||||
Dosage and administration details |
2 inhalations once daily
|
|||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Treatment Period
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Full Analysis Set
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Intention-to-treat | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
The FAS was used as the primary population for reporting efficacy data and to summarise baseline characteristics. This set comprised all patients randomised into the study who received at least 1 inhalation of investigational product and was analysed according to randomised treatment (intention-to-treat principle).
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
AZD7624 1.0 mg
|
||
Reporting group description |
- | ||
Reporting group title |
Placebo
|
||
Reporting group description |
- | ||
Subject analysis set title |
Full Analysis Set
|
||
Subject analysis set type |
Intention-to-treat | ||
Subject analysis set description |
The FAS was used as the primary population for reporting efficacy data and to summarise baseline characteristics. This set comprised all patients randomised into the study who received at least 1 inhalation of investigational product and was analysed according to randomised treatment (intention-to-treat principle).
|
|
|||||||||||||
End point title |
Time to first ExDo event | ||||||||||||
End point description |
the time to first event of moderate or severe COPD exacerbation or early drop-out related to worsening of COPD symptoms (ie, composite endpoint referred to as “ExDo”)
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
up to 12 weeks
|
||||||||||||
|
|||||||||||||
Notes [1] - There were too few events to estimate median using Kaplan Meier methodology |
|||||||||||||
Statistical analysis title |
Cox regression analysis | ||||||||||||
Statistical analysis description |
Hazard ratios, 95% CIs for hazard ratios, and p-values are estimated using a Cox regression model with treatment, country, LAMA maintenance treatment, age group, baseline FEV1 and sex as covariates
|
||||||||||||
Comparison groups |
AZD7624 1.0 mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
211
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority [2] | ||||||||||||
P-value |
= 0.2371 | ||||||||||||
Method |
Regression, Cox | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
1.39
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.81 | ||||||||||||
upper limit |
2.4 | ||||||||||||
Notes [2] - A hazard ratio greater than 1 indicates a higher rate of incidence in the first of the two groups. |
|
|||||||||||||
End point title |
Time to first moderate or severe COPD exacerbation or early drop-out | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 12 weeks
|
||||||||||||
|
|||||||||||||
Notes [3] - There were too few events to estimate median using Kaplan Meier methodology |
|||||||||||||
Statistical analysis title |
Cox regression analysis | ||||||||||||
Statistical analysis description |
Hazard ratio, 95% CI for hazard ratio, and p-value are estimated using a Cox regression model with treatment, country, LAMA maintenance treatment, age group, baseline FEV1 and sex as covariates.
|
||||||||||||
Comparison groups |
AZD7624 1.0 mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
211
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority [4] | ||||||||||||
P-value |
= 0.1261 | ||||||||||||
Method |
Regression, Cox | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
1.49
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.89 | ||||||||||||
upper limit |
2.5 | ||||||||||||
Notes [4] - A hazard ratio greater than 1 indicates a higher rate of incidence in the first of the two groups. |
|
|||||||||||||
End point title |
Time to first moderate or severe COPD exacerbation | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 12 weeks
|
||||||||||||
|
|||||||||||||
Notes [5] - There were too few events to estimate median using Kaplan Meier methodology [6] - There were too few events to estimate median using Kaplan Meier methodology |
|||||||||||||
Statistical analysis title |
Cox regression analysis | ||||||||||||
Statistical analysis description |
Hazard ratio, 95% CI for hazard ratio, and p-value are estimated using a Cox regression model with treatment, country, LAMA maintenance treatment, age group, baseline FEV1 and sex as covariates.
|
||||||||||||
Comparison groups |
AZD7624 1.0 mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
211
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority [7] | ||||||||||||
P-value |
= 0.1529 | ||||||||||||
Method |
Regression, Cox | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
1.53
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.85 | ||||||||||||
upper limit |
2.76 | ||||||||||||
Notes [7] - A hazard ratio greater than 1 indicates a higher rate of incidence in the first of the two groups. |
|
|||||||||||||
End point title |
Time to first moderate or severe COPD exacerbation (Anthonisens criteria) | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 12 weeks
|
||||||||||||
|
|||||||||||||
Notes [8] - There were too few events to estimate median using Kaplan Meier methodology [9] - There were too few events to estimate median using Kaplan Meier methodology |
|||||||||||||
Statistical analysis title |
Cox regression analysis | ||||||||||||
Statistical analysis description |
Hazard ratio, 95% CI for hazard ratio, and p-value are estimated using a Cox regression model with treatment, country, LAMA maintenance treatment, age group, baseline FEV1 and sex as covariates.
|
||||||||||||
Comparison groups |
AZD7624 1.0 mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
211
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority [10] | ||||||||||||
P-value |
= 0.8543 | ||||||||||||
Method |
Regression, Cox | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
0.93
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.43 | ||||||||||||
upper limit |
2.01 | ||||||||||||
Notes [10] - A hazard ratio greater than 1 indicates a higher rate of incidence in the first of the two groups. |
|
|||||||||||||
End point title |
Time to first symptom defined COPD exacerbation (EXACT daily diary) | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
up to 12 weeks
|
||||||||||||
|
|||||||||||||
Notes [11] - There were too few events to estimate median using Kaplan Meier methodology [12] - There were too few events to estimate median using Kaplan Meier methodology |
|||||||||||||
Statistical analysis title |
Cox regression analysis | ||||||||||||
Statistical analysis description |
Hazard ratios, 95% CIs for Hazard ratios, and p-values are estimated using a Cox regression model with treatment, country, LAMA maintenance treatment, age group, baseline FEV1 and sex as covariates.
|
||||||||||||
Comparison groups |
AZD7624 1.0 mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
211
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority [13] | ||||||||||||
P-value |
= 0.5381 | ||||||||||||
Method |
Regression, Cox | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
0.86
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.54 | ||||||||||||
upper limit |
1.38 | ||||||||||||
Notes [13] - A hazard ratio greater than 1 indicates a higher rate of incidence in the first of the two groups. |
|
|||||||||||||
End point title |
Frequency of ExDo events | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 12 weeks
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Frequency of ExDo events, negative binomial model | ||||||||||||
Statistical analysis description |
Analysis model: rates, rate ratios, and p-value are from a negative binomial regression analysis, with treatment, country, LAMA maintenance treatment, age group, baseline FEV1 and sex included in the model as covariates.
|
||||||||||||
Comparison groups |
AZD7624 1.0 mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
211
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.249 | ||||||||||||
Method |
Negative binomial regression | ||||||||||||
Parameter type |
Rate ratio | ||||||||||||
Point estimate |
1.33
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.82 | ||||||||||||
upper limit |
2.16 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
0.33
|
|
|||||||||||||
End point title |
Frequency of moderate or severe COPD exacerbations or early drop-out | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 12 weeks
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
negative binomial model | ||||||||||||
Statistical analysis description |
Analysis model: rates, rate ratios, and p-value are from a negative binomial regression analysis, with treatment, LAMA maintenance treatment, age group, baseline FEV1 and sex included in the model as covariates.
|
||||||||||||
Comparison groups |
AZD7624 1.0 mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
211
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.157 | ||||||||||||
Method |
Negative binomial regression | ||||||||||||
Parameter type |
Rate ratio | ||||||||||||
Point estimate |
1.4
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.88 | ||||||||||||
upper limit |
2.21 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
0.33
|
|
|||||||||||||
End point title |
Frequency of moderate or severe COPD exacerbations | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 12 weeks
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Negative binomial model | ||||||||||||
Statistical analysis description |
Analysis model: rates, rate ratios, and p-value are from a negative binomial regression analysis, with treatment, country, LAMA maintenance treatment, age group, baseline FEV1 and sex included in the model as covariates.
|
||||||||||||
Comparison groups |
AZD7624 1.0 mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
211
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.129 | ||||||||||||
Method |
Negative binomial regression | ||||||||||||
Parameter type |
Risk ratio | ||||||||||||
Point estimate |
1.5
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.89 | ||||||||||||
upper limit |
2.52 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
0.4
|
|
|||||||||||||
End point title |
Frequency of moderate or severe COPD exacerbations (Anthonisens criteria) | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
up to 12 weeks
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Negative binomial model | ||||||||||||
Statistical analysis description |
Analysis model: rates, rate ratios, and p-value are from a negative binomial regression analysis, with treatment, LAMA maintenance treatment and sex included in the model as covariates.
|
||||||||||||
Comparison groups |
AZD7624 1.0 mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
212
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.751 | ||||||||||||
Method |
negative binomial regression | ||||||||||||
Parameter type |
Rate ratio | ||||||||||||
Point estimate |
1.12
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.55 | ||||||||||||
upper limit |
2.29 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
0.41
|
|
|||||||||||||
End point title |
Frequency of symptom defined COPD exacerbations (EXACT daily diary) | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 12 weeks
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Negative binomial model | ||||||||||||
Statistical analysis description |
Analysis model: rates, rate ratios, and p-value are from a negative binomial regression analysis, with treatment, LAMA maintenance treatment, baseline FEV1 and sex included in the model as covariates.
|
||||||||||||
Comparison groups |
AZD7624 1.0 mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
211
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.44 | ||||||||||||
Method |
Negative binomial regression | ||||||||||||
Parameter type |
Rate ratio | ||||||||||||
Point estimate |
0.84
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.55 | ||||||||||||
upper limit |
1.3 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
0.19
|
|
|||||||||||||
End point title |
Transitional Dyspnoea Index - Total Daily Score | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
up to 12 weeks
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Mixed model repeated measures analysis | ||||||||||||
Statistical analysis description |
Results obtained from mixed model repeated measures analysis, fitting treatment, country, LAMA maintenance treatment, visit and
treatment by visit interaction as fixed effects, patient as a random effect and baseline assessment as a continuous covariate. An unstructured covariance matrix has been used.
|
||||||||||||
Comparison groups |
AZD7624 1.0 mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
202
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority [14] | ||||||||||||
P-value |
= 0.3468 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||
Point estimate |
-0.29
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.9 | ||||||||||||
upper limit |
0.32 | ||||||||||||
Notes [14] - Positive values for a difference show AZD7624 to have a favourable outcome compared to Placebo. |
|
|||||||||||||
End point title |
St George Respiratory Questionnaire for COPD patients (SGRQ-C) | ||||||||||||
End point description |
Change from pre study-treatment baseline in Health related quality of life (as assessed by St George Respiratory Questionnaire for COPD patients [SGRQ-C] total score)
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 12 weeks
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Mixed model repeated measures analysis | ||||||||||||
Statistical analysis description |
Results obtained from mixed model repeated measures analysis, fitting treatment, country, LAMA maintenance treatment, visit and
treatment by visit interaction as fixed effects, patient as a random effect and baseline assessment as a continuous covariate. An unstructured covariance matrix has been used.
|
||||||||||||
Comparison groups |
AZD7624 1.0 mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
201
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority [15] | ||||||||||||
P-value |
= 0.5909 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||
Point estimate |
0.95
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-2.53 | ||||||||||||
upper limit |
4.43 | ||||||||||||
Notes [15] - Negative values for a difference show AZD7624 to have a favourable outcome compared to Placebo. |
|
|||||||||||||
End point title |
Spirometry assessments - FEV1 | ||||||||||||
End point description |
Pulmonary function measured as changes from baseline (post bronchodilator at Visit 3) in trough Forced Expiratory Volume in 1 second (FEV1)
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 12 weeks
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
mixed model repeated measures analysis | ||||||||||||
Statistical analysis description |
Results obtained from mixed model repeated measures analysis, fitting treatment, country, LAMA maintenance treatment, visit,
sex, smoking history and treatment by visit interaction as fixed effects, patient as a random effect, and baseline assessment, age, BMI and height as continuous covariates. A compound symetry covariance matrix has been used.
|
||||||||||||
Comparison groups |
AZD7624 1.0 mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
207
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority [16] | ||||||||||||
P-value |
= 0.5144 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||
Point estimate |
0.02
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.03 | ||||||||||||
upper limit |
0.07 | ||||||||||||
Notes [16] - Positive values for a difference show AZD7624 to have a favourable outcome compared to Placebo. |
|
|||||||||||||
End point title |
Spirometry Assessments - FVC | ||||||||||||
End point description |
Pulmonary function measured as changes from baseline (post bronchodilator at Visit 3) in trough Forced Vital Capacity (FVC)
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 12 weeks
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Mixed model repeated measures analysis | ||||||||||||
Statistical analysis description |
Results obtained from mixed model repeated measures analysis, fitting treatment, country, LAMA maintenance treatment, visit,
sex, smoking history and treatment by visit interaction as fixed effects, patient as a random effect, and baseline assessment, age, BMI and height as continuous covariates. A compound symmetry covariance matrix has been used.
|
||||||||||||
Comparison groups |
AZD7624 1.0 mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
207
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority [17] | ||||||||||||
P-value |
= 0.5416 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||
Point estimate |
-0.02
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.1 | ||||||||||||
upper limit |
0.05 | ||||||||||||
Notes [17] - Positive values for a difference show AZD7624 to have a favourable outcome compared to Placebo. |
|
|||||||||||||
End point title |
Spirometry assessments - FEV1/FVC | ||||||||||||
End point description |
Pulmonary function measured as changes from baseline (post bronchodilator at Visit 3) in trough FEV1/FVC
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 12 weeks
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Mixed model repeated measures analysis | ||||||||||||
Statistical analysis description |
Results obtained from mixed model repeated measures analysis, fitting treatment, country, LAMA maintenance treatment, visit,
sex, smoking history and treatment by visit interaction as fixed effects, patient as a random effect, and baseline assessment, age, BMI and height as continuous covariates. A compound symetry covariance matrix has been used.
|
||||||||||||
Comparison groups |
AZD7624 1.0 mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
207
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority [18] | ||||||||||||
P-value |
= 0.1965 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||
Point estimate |
0.01
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0 | ||||||||||||
upper limit |
0.02 | ||||||||||||
Notes [18] - Positive values for a difference show AZD7624 to have a favourable outcome compared to Placebo. |
|
|||||||||||||
End point title |
EXACT for Respiratory Symptoms (E-RS) | ||||||||||||
End point description |
Symptoms of COPD (using the EXACT for Respiratory Symptoms [E-RS] Total Score, a subset of items from the EXACT diary)
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 12 weeks
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Mixed model repeated measures analysis | ||||||||||||
Statistical analysis description |
Results obtained from mixed model repeated measures analysis, fitting treatment, country, LAMA maintenance treatment, visit and
treatment by visit interaction as fixed effects, patient as a random effect and baseline assessment as a continuous covariate. An unstructured covariance matrix has been used.
|
||||||||||||
Comparison groups |
AZD7624 1.0 mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
211
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority [19] | ||||||||||||
P-value |
= 0.5474 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||
Point estimate |
-0.37
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-1.6 | ||||||||||||
upper limit |
0.85 | ||||||||||||
Notes [19] - Negative values for a difference show AZD7624 to have a favourable outcome compared to Placebo. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Adverse events occurring during the treatment period or 2-week follow-up period are reported
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
18.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
AZD7624 1.0 mg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Total
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 2% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |